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Abstract (250 word limit, currently 250) 37 
Background:  Patients with multiple drug allergy labels (MDAL) present a challenging barrier to 38 
patient care.  39 
Objective:  To assess the efficacy, safety and effectiveness of removing MDAL in a single clinic 40 
visit. 41 
Methods: Retrospective chart review was performed from October 1, 2014 to October 31, 2018 on 42 
MDAL patients who had electronic health record (EHR) allergy label to two or more drug and who were 43 
delabeled to ≥1 drug.. Our primary outcome was the number of allergy labels tested and 44 
removed, at a single or multiple visits. Post-visit surveys were administered to patients, their 45 
pharmacies and primary care physicians (PCP) for patients delabeled following an EHR 46 
transition from November 2, 2017 to October 31
st
  2018 (n=184). 47 
 48 
Results: Among 536 patients meeting inclusion criteria, 916/943 (97.1%) of tested allergy labels were 49 
removed from the EHR . Most patients 461/536 (86.0%) were tested, challenged and delabeled in 50 
a single visit,  to ≥ 1 drug, although 134/536 (25%) still had evidence of > 1 label at one year. In 51 
surveys, 90/171 (52.6%) of responding pharmacies and 122/168 (72.6%) of PCPs contacted had 52 
removed drug labels from the EHR as a result of the recommendations from the patient’s drug 53 
allergy evaluation.  Overall, 91/142 (64.1%) of MDAL patient survey respondents were willing to 54 









Conclusions: MDAL patients can be safely delabeled to multiple drugs in one visit, however 57 
effectiveness barriers were identified.  Reinforcement of drug allergy label removal information 58 
to patients, pharmacies and primary care providers presents a targeted area for improvement. 59 
 60 
 61 









What is already known about this topic?  64 
Most drug allergy labels in the EHR are not consistent with a hypersensitivity reaction on 65 
history.  Multiple drug allergy labels (MDAL) can delay adequate patient care, increase 66 
morbidity, and are challenging and time consuming to evaluate. 67 
What does this article add to our knowledge? 68 
Patients with MDAL can be safely delabeled to multiple drugs with a high degree of efficacy, 69 
however there are long-term effectiveness concerns related to reacquisition of a label or 70 
incomplete delabeling. 71 
How does this study impact current management guidelines?  72 
There is no evidence-based consensus on how to manage patients with multiple drug allergies 73 
in allergy and immunology practice guidelines. Our study suggests that many MDAL patients 74 
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Drug allergy labels such as penicillin allergy have been shown to adversely affect both patient 103 
care and public health.
1
 An increasing number of patients carry the burden of multiple drug 104 
allergy labels (MDAL) acquired and accumulated over time leading to limitations in their care 105 
options.  Recent studies have shown the overall prevalence of patients who report MDAL that 106 
could comprise both intolerances and/or true hypersensitivities to be 1.2 to 6.4%.
2
 Current 107 
specialty allergy practices cannot typically manage the high burden of patients with MDAL and 108 
it is unusual in an allergy practice to test for or remove the allergy label from more than one 109 
drug or class of drugs per visit.  Traditionally, delabeling of multiple drug allergies would 110 
therefore require multiple appointments over a long period of time.  Such approaches can be 111 
inefficient and mays lead to suboptimal care for patients due to delays in essential treatment, 112 
and increased morbidity due to unnecessary avoidance of first-line or necessary drugs. 113 
 114 
Nomenclature used to define patients labeled as having multiple drug allergies include multiple 115 
drug allergy syndrome (MDAS), multiple drug intolerance syndrome (MDIS) and multiple drug 116 
hypersensitivity (MDH). MDAS has been used to describe patients with adverse drug reactions 117 
(ADR) to two or more structurally unrelated drugs with an underlying mechanism that through 118 
clinical phenotyping is suspected to be immune-mediated 
2
. MDH is defined as confirmed drug 119 
hypersensitivity to at least 2 chemically and pharmacologically unrelated drugs in the same 120 
patient 
3, 4
. Multiple drug Intolerance syndrome (MDIS) is a term used to describe patients with 121 
three or more ADR to structurally unrelated drugs without an underlying immunological 122 
mechanism 
5









By reviewing the drug allergy box of patients it is easy to recognize that not all patients with 125 
multiple drug allergies listed in their chart can be easily classified to fall within these 126 
definitions.
6, 7
 In addition, it is practical and relevant to recognize that drug allergy labels 127 
documented in the electronic health record (EHR) can have an effect on patient care and 128 
delivery whether the initial event leading to labeling was an intolerance, a toxicity, or a 129 
hypersensitivity reaction (HSR).
6
  We therefore sought to evaluate the approach to what we 130 
have collectively called MDAL which we defined as patients with two or more drug allergy 131 
labels in the allergy box in the EHR regardless of the underlying mechanism leading to their 132 
application.  Because this group of patients may have different behaviors to care-seeking and 133 
the perception of symptoms during medical treatment, we sought to assess the efficacy, safety 134 
and effectiveness of removing drug allergy labels in patients identified as MDAL. Further, we 135 
sought to understand how consistently and effectively patients, pharmacies and primary care 136 
physicians receive, understand and modify their records based on the information that was 137 

















Study Design 148 
We evaluated the safety and efficacy of in-clinic testing performed on MDAL patients, either at 149 
a single visit or over multiple visits.  We evaluated the effectiveness of our testing through a  150 
mixed methods approach by both a retrospective chart review measuring the durability of 151 
delabeling and drug usage following delabeling along with a survey of patients, their 152 
pharmacists and their providers. Our review and follow-up surveys were approved by the 153 
VUMC IRB (#161455). 154 
 155 
Retrospective Cohort Design: 156 
We conducted a standardized retrospective chart review of MDAL patients seen in the drug 157 
allergy clinic at the Vanderbilt Asthma, Sinus and Allergy Program (VASAP), Vanderbilt 158 
University Medical Center (VUMC) by a single physician who provided these services from 159 
October 1, 2014 through October 31, 2018.  Standardized retrospective chart reviews were 160 
performed on all new patients seen over this period to obtain information about patient age, 161 
sex, race, number of allergy labels, drugs to which the patient was labeled as allergic, the 162 
testing that was performed on the patient, the testing results, the clinical recommendations 163 
and whether delabeling occurred in the chart.  164 
 165 
Our inclusion criteria were all patients at least 18 years of age who had two or more drug 166 








recommendations and label removal from VUMC EHR following one or more visits to the drug 168 
allergy clinic between October 1
st
 2014 to October 31
st
 2018.  These patients had skin testing to  169 
one or more drugs in either a single or multiple clinic visits and were followed up for tolerance 170 
within 24 hours of their clinic visit by testing nurses.  We excluded patients who did not have at 171 
least two drug allergy labels that would be eligible for any type of attempted delabeling 172 
procedure, for example, severe cutaneous adverse reactions (SCARs) such as drug reaction with 173 
eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome and toxic epidermal 174 
necrolysis (SJS/TEN) or those with  severe drug-induced organ involvement, or another toxicity 175 
where rechallenge would not be attempted (e.g. fluoroquinolone associated tendinopathy). 176 
Out of 793 charts reviewed, 675 patients were identified to have at least two drug allergies, of 177 
which 536 were delabeled to at least one allergy, making them eligible for inclusion in our two 178 
studies. 179 
 180 
The VASAP drug allergy clinic has developed a strategy to test and challenge patients to 181 
multiple drugs at a single visit. Usually drug challenges are done sequentially over a 4-6 hour 182 
period after initial skin testing, which rules out high risk anaphylaxis or IgE-mediated reactions. 183 
The rationale for this approach is that the vast majority of patients give histories of either ill-184 
defined, remote and unknown reactions or  benign reactions at low risk for rechallenge 185 
morbidity.  We were also primarily interested in ruling out and delabeling patients of 186 
immediate reactions  by verifying tolerance of observed challenges in a single visit. Our primary 187 
outcome was the number of allergy labels tested and removed at a single visit or multiple visits.  188 







label reacquisition or incomplete delabeling (“delabeling effectiveness”) within one year of 190 
allergy label removal and the effectiveness of communication of results of testing and 191 
delabeling to patients, their primary care providers and their pharmacies. 192 
 193 
Survey Design: 194 
At the end of every patient testing visit in the drug allergy clinic, an after visit summary with 195 
standardized key information on every allergy label discussed and/or evaluated is provided.  196 
This after visit summary includes a customized visit table that upon later transition to Epic was 197 
a customized Epic dot phrase with several pull down options to standardize reporting of the 198 
type of reaction (immediate versus delayed), the type of testing done and the conclusions of 199 
testing. (Figure 1).  This table summarizes the patient’s initial drug allergy label, the history of 200 
the index reaction, the type of testing done during the visit, the results of that testing that 201 
includes recommendations regarding the label in the future and suggested follow-up. Although 202 
the presence of an  electronic health record, in many countries has made it easier integrate 203 
information across clinics, hospitals, and pharmacies there is no universal process across 204 
different healthcare systems and there are still hurdles in this process. In the US in particular 205 
HIPAA and privacy laws have created a barrier to universal sharing of information.   However, 206 
these types of  hurdles can  still be significant across many different healthcare systems even 207 
with the advantage of an EHR.   Therefore, once a drug allergy is removed from the EHR, this 208 
information is not automatically and electronically available to PCPs with different EHR systems 209 








updated as necessary over time and subsequent visits, is provided to every patient, and also 211 
faxed to their pharmacies and primary care provider.  212 
 213 
To measure the effectiveness of the visit communication strategies and testing for MDAL with 214 
at least one year following testing, we next surveyed a cross-sectional sample of all new MDAL 215 
patients (n=170) seen from November 2,
  
2017 to October 31, 2018, within our Epic EHR. 216 
Surveys were distributed to the MDAL patients, their pharmacies and primary care physicians to 217 
evaluate the effectiveness of our communication strategy. Patient surveys were completed by 218 
an emailed self-administered survey or by a provider administered phone survey, depending 219 
upon patient preference and availability. Pharmacy and primary care clinic surveys were 220 
administered by two trained providers and completed over the phone.  221 
 222 
Our primary survey effectiveness outcomes were drug utilization following testing, the 223 
proportion of patients who were willing to take drugs to which they were delabeled, and our 224 
effectiveness at communicating the results of testing to our patients, their primary care 225 
physicians and their pharmacies.  We measured our effectiveness in communication to PCPs 226 
and pharmacies based upon whether they had 1) documented receipt of our communications 227 
and 2) acted on these communications by removing the relevant allergy labels in their chart or 228 
pharmacy records.   229 
Overall “delabeling effectiveness” was measured as a composite measure that would have  230 
included either  “incomplete delabeling” or “relabeling”.  Incomplete delabeling refers to 231 








clinic visit but not removed by their PCP or pharmacist despite receiving acknowledgement of 233 
after visit summaries. “Relabeling”  or reacquisition of a drug allergy label was defined as a label 234 
that was actively added back to the EHR by patients, physicians or pharmacies after being 235 




Retrospective Cohort Characteristics: 240 
Out of 793 patients seen from October 1
st
 2014 to October 31
st
 2018 in the VASAP drug allergy 241 
clinic, 675 patients had more than two eligible labels documented in the EHR. Of these patients, 242 
536 patients were delabeled to at least 1 drug ., and thereby met criteria for inclusion in our 243 
MDAL cohort. In total, 257/793 patients were excluded as they did not get delabeled to at least 244 
one drug or did not have at least two drug allergy labels that were associated with clinical 245 
phenotypes eligible for attempted delabeling.  246 
 247 
MDAL Patient Characteristics: 248 
The majority of our 536 MDAL patients seen from October 1
st
 2014 to October 31
st
 2018 were 249 
female (76.7%) and of European-American descent (91.6%) (Table 1).  The median number of 250 
drug allergy labels that an MDAL patient brought into an evaluation was 5 (IQR 3,8).  251 
Hypertension and obstructive lung disease were commonly seen in our cohort. There were no 252 
significant diffeences in psychiatric comorbidities (such as anxiety disorders, depression and 253 








=0.1, p-value for anxiety=0.84) (4). Comparison of characteristics of the MDAL cohort and the 255 
general clinic population seen within the same time period is shown in Table 1.  256 
 257 
Out of 943 total labels that were tested in these 536 patients, 916/943 (97.1%) labels were 258 
removed (see Table 2).  A complete breakdown of cases of positive testing for all drugs is in 259 
Table 3. A single visit was able to test, challenge, and delabel patients to more than one drug in 260 
86% (461/536) of cases. The median number of labels removed was 2 IQR [1,3].  Comparing 261 
single versus multiple visits, the median numbers of labels removed in a single visit (n=461) was 262 
2 [IQR 1,2] compared to multiple visits (n= 75) was 3 [IQR 1,4]( p=0.445). Number of patients 263 
who had EHR record of receiving penicillin within 1 year was 94/461 (20.3%) when patients 264 
were seen in a single visit versus 18/75 (24%) when seen in multiple visits (p=0.530). 112/461 265 
(24.2%) patients reacquired the drug allergy label in EHR when seen in a single visit compared 266 
to 22/75 (29.3%) who were seen in multiple visits (p=0.176). Of drug allergy labels tested by a 267 
formal in clinic testing procedure (n=943) these were classified as immediate (<1hour) 148/943 268 
(15.6%), delayed (>1 hour) 427/943 (45.2%), unknown timeline 136/943 (14.4%) and 269 
intolerance 54/943 (5.7%).   270 
 271 
Subsequent to their evaluation in the VASAP Drug Allergy Clinic, 112/390 (28.7%) patients had 272 
an EHR record of penicillin treatment in the year after testing and delabeling. However, upon 273 
chart review performed at a minimum of 12 months after their visit, 134/536 (25%) of MDAL 274 
patients had evidence of being relabeled to at least one drug that had been removed in the 275 







reacquire drug allergy labels after negative testing is enumerated in Table 4. Patients who had a 277 
higher number of initial labels had a higher likelihood of having drug labels reapplied to which 278 
they had been delabeled in the EHR. Psychiatric comorbidities like anxiety, depression and 279 





Survey Results: 285 
 286 
Patient Survey Results: All 184 new MDAL patients seen from November 2,
 
2017 to October 31, 287 
2018 were contacted through phone call or email, of whom 142/184 (77.2%) consented to the 288 
survey. Amongst those MDAL patients who responded, 123/142 (86.6%) felt as though they 289 
were aware of the conclusions of our testing and recommendations at the time of survey. 290 
However, only 91/142 (64.1%) MDAL patients were willing to take the drugs they were 291 
delabeled to in our clinic.  Of interest, 85/142 (59.9%) reported that they had already taken and 292 
tolerated at least one drug after the label had been removed. At the time of survey, 62/85 293 
(72.9%) of patients who had taken a delabeled drug reported ongoing willingness to take any 294 
drugs they were delabeled to, 22/85 (25.9%) reported having taken a delabeled drug but were 295 
now unwilling to do so when surveyed, and 1/85 (1.2%) reported being uncertain about their 296 
willingness to take delabeled drugs again. Many patients who had both been negative on 297 








labeled still expressed doubts. Despite counseling in clinic that their risk was at the population 299 
level,  they articulated that they were not convinced that they would be free of an allergic 300 
reaction in the future. 301 
 302 
Pharmacy Survey Results: 303 
 304 
171/184 (92.9%) of the MDAL survey patients’ pharmacists contacted were willing to 305 
participate in our surveys. From these 171 pharmacists contacted we became aware that there 306 
were several apparent hurdles encountered that led to drug allergy labels not being removed in 307 
the pharmacy systems.  90/171 (52.6%) acknowledged receipt of the after visit summary 308 
documenting the allergy evaluation and had removed the relevant allergy labels from their 309 
pharmacy system.  However, the other 81/171 (47.4%) pharmacies had not removed any drug 310 
allergy labels outlined in our after visit summary. Out of the 81 pharmacies, 45 (55.6%) that did 311 
not delabel the drug allergies in their pharmacy EHR requested after visit summaries to be 312 
faxed again with clear instructions from the provider above and beyond the details in the after 313 
visit summary to specifically remove the label.  Notably, 31/81 (38.3%) were comfortable 314 
delabeling the drug allergy label over the phone at the time of our follow-up survey.(Table 5 ) In 315 
addition, 3/81 (3.7%) of pharmacies reported that written information was insufficient and that 316 
they would only remove an allergy label after an additional phone call from the allergy clinic. 317 
Only one pharmacy out of 171 contacted had an EHR system with capacity for scanning 318 
documentation from our after visit summary and drug allergy testing table directly into their 319 









Primary Care Physician (PCP) Survey Results: 322 
168/184 (91.3%) of the MDAL patients’ PCP offices contacted were willing to participate in our 323 
surveys. 122/168 (72.6%) of PCPs removed drug labels from the EHR as a result of the patient’s 324 
drug allergy evaluation and 116/168 (69%) of PCP offices reported receipt and documentation 325 
of the drug allergy table summarizing testing and results. Of the PCP offices that did not delabel 326 
the relevant drug allergies from their EHR, 24/46 (52.2%), requested the after visit summaries 327 
to be faxed again with clearer direct instructions to remove the label.  328 
 329 
Discussion: 330 
Hypersensitivity reactions (HSR) are ADRs that are immunologically mediated.
8
  It is of great 331 
practical significance to be able to definitively identify labels of true immunologically mediated 332 
hypersensitivity to an implicated drug and structurally related drugs and differentiate those 333 
from labels due to benign reactions or non-immune mediated drug intolerances which are not a 334 
contraindication to future dosing. Notably, most documented drug allergy labels in the EHR are 335 
not representative of high risk  or true immunologically-mediated adverse drug reactions 
6, 7, 9
 336 
.As a result, many patients and physicians are faced with a burden of MDAL resulting in 337 
unnecessary avoidance.  Such avoidance can lead to prescribing medications of different classes 338 
with potentially reduced efficacy,  polypharmacy, and ultimately pose a threat to patient safety 339 
and public health.  340 
 341 
Patients with MDAL can be a burden for allergy practices as removing these labels may involve 342 








study we demonstrated that a total of 916/943 (97.1%) allergy labels tested in 536 patients 344 
were ultimately removed from the VUMC EHR. The majority of patients 461/536 (86.0%) were 345 
tested, challenged and delabeled in a single visit to one or more drugs.  The procedures were 346 
safe and well tolerated.  347 
 348 
We have shown that delabeling efforts were largely successful in our MDAL patients, that it was 349 
possible to delabel patients in a single visit.  Importantly, our population had a very low risk for  350 
positive drug challenge reactions or need for blinded drug challenges.  However we did notice a 351 
sizable delabeling effectiveness gap whereby 134/536 (25%) of patients in the absence of a new 352 
clinical reaction and at a minimum of one year following their testing appointment were found 353 
to be labeled to one or more drugs to which they had originally been delabeled.  In addition,  354 
approximately one-third of our delabeled patients when questioned in our follow-up survey,  355 
reported incomplete willingness to take drugs in the future that they had been delabeled to, 356 
despite the fact they had clear negative skin testing and oral challenges. On the other hand, 357 
many patients did believe in testing, as 85/142 (59.9%) reported that they had already had an 358 
indication for and taken at least one drug for which their allergy label had been removed, 72.9% 359 
(62/85) of whom remained willing to take drugs that they were delabeled to when surveyed. 360 
112/390 (28.7%) patients tested and delabeled to penicillin in particular had an EHR record of a 361 
later tolerated five or greater day course of penicillin treatment.  362 
 363 
Previous studies have shown that the odds of anxiety and depression increase with the number 364 
of allergy labels across drug classes reported in the allergy box
2








statistical difference in psychiatric comorbidities (i.e. anxiety, depression and bipolar disorder) 366 
overall between those who were delabeled more than one drug and those who  were either 367 
incompletely delabeled or reacquired a label,  it is notable that psychiatric comorbidities  were 368 
seen in 43%% of our cohort, which could as suggested by the literature contribute to the 369 
primary acquisition of multiple labels 
10
 . Notably the number of initial labels did predict the 370 
likelihood of incomplete delabeling or label reacquisition. The delivery and receipt of 371 
information regarding drug delabeling  in specific populations such as the elderly and those 372 
with  MDAL histories that include more than five labels may require particular care and 373 
reinforcement to avoid incomplete delabeling and reacquisition.  374 
 375 
Also notable in our study was the problem of lack of receipt, acknowledgement and delabeling 376 
of drug allergy labels by pharmacies and primary care physicians, which contributed 377 
significantly to the delabeling effectiveness gap. Our study reinforces that in order to improve 378 
delabeling effectiveness,  communication to pharmacies must be further reinforced as 379 
traditional retail pharmacies do not have the ability to scan after visit summaries into their EHR, 380 
and only 52.6% had removed drug allergy from their EHR with one communication attempt. 381 
Primary care physicians complete drug allergy delabeling in their EHR at a higher rate than 382 
pharmacies which may be a reflection  of  their direct role in referring patients to allergy clinics 383 
for assessment of MDAL, and more direct contact and communication between physicians and 384 










Overall, our study of the safety and efficacy and effectiveness of drug allergy label removal in 388 
MDAL shows that it is feasible and effective to do this in a single visit and in fact for antibiotics 389 
and other drugs where delabeling maybe a critical part of the patient’s clinical care,  we may 390 
capture a higher proportion of patients within a single visit rather than several follow-up visits. 391 
Importantly patients tolerated multiple challenges in a single visit and on 24 hour nursing 392 
phone follow-up those who had been immediately delabeled did not express allergic signs or 393 
symptoms and 100% remained delabeled.  We acknowledge that one limitation of our study is 394 
its generalizability.  Our study population was  over-represented by adult women of European 395 
ancestry who in many cases were willing to attend a several hours long clinic for multiple drug 396 
delabeling. Patients not willing or able to go through this would have self-excluded.  The 397 
generalizability to non-White populations and women remains to be seen,  however the 398 
population of MDAL in general across North America and Europe where this has primarily been 399 
reported is enriched with this demographic.  Of significance and contrary to what is often 400 
reported in the literature involving patients with MDIS or MDAS, none of our MDAL patients 401 
failed primary delabeling that then required follow-up for double blind challenges. However, a 402 
number of delabeling effectiveness hurdles were identified mainly surrounding reinforcement 403 
of messages related to removal of drug labels, reinforcement of messages to patients 404 
particularly in the setting of patients who have more than five drug allergy labels at original 405 
assessment and clear communication to pharmacists and PCP. We have taken this forward to 406 
utilize the knowledge we have gained to design interventions that improve the effectiveness of 407 
care of patients with MDAL. These steps  include improved  communication to pharmacy and 408 








and pharmacies to reinforce message of drug allergy delabeling and have direct discussion with 410 
them.  We are also exploring direct and automated messaging and alerts to pharmacy and 411 
providers to reinforce changes in the patient’s drug allergy label information and interval 3, 6, 412 
12  month and 2 year follow-up communications to patients to follow future drug utilization 413 
and reinforce safety of future drug use and clinic procedures and delabeling, including the 414 
routine use of physical and virtual wallet-cards and smartphone passports
9
 (Figure 2). 415 
 416 
Conclusions:  417 
In conclusion, a single  allergy visit that includes same day testing and delabeling of MDAL 418 
appears  to be very well tolerated and has high efficacy and safety to remove multiple allergy 419 
labels.  Importantly in this mixed-methods retrospective cohort and survey study we identified 420 
some longer-term delabeling effectiveness hurdles  primarily related to poor understanding or 421 
communication gaps in appropriately relaying after visit information and delabeling instructions 422 
to pharmacists and PCPs.  This was evidenced by approximately one-third of  patients  on 423 
follow-up who had  drug allergy labels documented in their EHR for drugs where this label had 424 
been previously removed.   Further efforts are needed to improve the effectiveness of drug 425 
allergy label removal in MDAL patients.   This should include research to identify predictors and 426 
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Figure Legends: 466 
 467 
Figure 1: Drug allergy clinic after visit summary as populated in EHR system using a dotphrase. 468 
 469 
 470 








Table 1: Comparison of Characteristics of MDAL cohort and the general clinic 
population 
 General clinic 
population= 793  
MDAL n= 536 
Age- Median [IQR)  57 (42,67) 60 [47, 70] 
Female  570 (71.9%) 408 (76.7%) 
Ancestry:   
European American  673 (84.7%) 491 (91.6%) 
African American 52 (6.6%) 32 (6%) 
Asian American 8 (1.01%) 5 (0.9%) 
Native American 4 (0.5%) 2 (0.4%) 
Hispanic/Latino American 18 (2.3%) 2 (0.4%) 
 Other 2 (0.2%) 1 (0.2%) 
Median number of drug allergies (IQR) 5 [3.8] 5 [3,8] 
Medical Comorbidities    
Hypertension 331 (41.8%) 165 (30.8%) 
Asthma/COPD 161 (20.3%) 139 (25.9%) 
History of Depression 140 (17.7%) 118 (22.0%) 
History of Anxiety Disorder 132 (16.7%) 92 (17.2%) 
Diabetes 147 (18.5%) 91 (17.0%) 








Autoimmune Disease 100 (12.6%) 37 (6.9%) 
Transplant Recipient 43 (5.4%) 33 (6.2%) 
Chronic Urticaria/Angioedema 41 (5.2%) 30 (5.6%) 
History of Bipolar Disorder 18 (2.3%) 21 (3.9%) 
Cystic Fibrosis 30 (3.8%) 19 (3.5%) 
Primary Immune Deficiency 81 (10.2%) 18 (3.4%) 
HIV 72 (9.1%) 15 (2.8%) 
Dementia 14 (1.8%) 9 (1.7%) 




















Penicillin Skin testing* and 
oral challenge 
393 390 






Single or graded 
oral challenge  
177 167 
Fluoroquinolones Skin testing and 
oral challenge 
97 93 
NSAIDs Graded oral 
challenge 
27 25 
Vancomycin Historical 12 12 
Radiocontrast Skin testing 18 18 
Azithromycin Single or graded 
oral challenge 
10 10 
*Penicillin reagents used were Penicillin G 1000 U/mL, Penicillin G 
10,000 U/mL, Pre pen (Major determinant), Minor Determinant Mixture 









Table 3: Breakdown of cases in which drug allergy testing was positive  













IDT =Intradermal Testing 
* 2 Immediate IDT to clindamycin, 1 SPT to Aztreonam, 1 SPT to Gentamycin 
**  3 Immediate IDT ondansetron),  1 Immediate IDT to oxaliplatin,  1 immediate IDT to 
Polyethylene glycol 3350 , 1  positive delayed IDT to lidocaine, 1  immediate IDT to 
Insulin 
±  One Positive oral challenge with flushing and throat itching within 15 minutes 
resolved with oral diphenhydramine  and epinephrine 0.3mg IM. 
Ψ  One Asthma exacerbation 20 mins after 325mg of Aspirin resolved with albuterol 
nebulize treatment and intramuscular steroid. Another positive challenge with nasal 









Table 4: Comparisons amongst patients who did vs. did not reacquire 
labels after negative testing 













Age- Median [IQR]  61 [47, 70] 60 [46,70] 0.41 
Female  293 (72.8%) 107 (79.8%) 0.13 
Ancestry:   0.68 
European American 352 (87.5%) 126 (94%)  
Non European American 50 (12.4%)* 8 (5.9%)**  
Number of Drug Allergy Labels - 
Median [IQR] 
4 [3,7] 6 [4,10] <0.0005 
Medical Comorbidities:    
Asthma/COPD 89 (22.1%) 46 (34.3%) 0.009 
Diabetes 60 (14.9%) 29 (21.6%) 0.10 
Hypertension 116 (28.8%) 46 (34.3%) 0.34 
History of Malignancy 53 (13.1%) 21 (15.7%) 0.57 
History of Depression 89 (22.1%) 28 (20.9%) 0.63 
History of Anxiety 
Disorder 
66 (16.4%) 22 (16.4%) 0.88 
Autoimmune Disease 27 (6.7%) 10 (7.5%) 0.85* 








continuous variables, and using Pearson’s chi-square test for categorical 
variables, except where denoted by a*, indicating the use of Fisher’s exact test. 
 
 
*Other Ancestry includes: African American: 25 (6.2%), Native American 
2 (0.4%), Asian American 5 (1.2%),Hispanic/Latino: 1 (0.2%), Hawaiian 
Pacific Islander: 1 (0.2%) 
** Other Ancestry includes: African American: 7 (5.2%), Native American 
0 (0%), Asian American 0 (0%),Hispanic/Latino: 1 (0.74%), Hawaiian 








 Table 5: Outcomes and Interventions requested by pharmacies that did not 
remove drug allergy labels after our standard communications, to improve drug 
allergy label removal, n=81 
Re-send drug allergy clinic note 
summarizing testing and results (with 
clear instructions to remove drug 
allergy label) 
45 (55.6%) 
Phone call from clinic in addition to 
drug allergy clinic note 
3 (3.7%) 
Patient permission/patient to bring 
drug allergy clinic after visit summary 
2 (2.5%) 
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